You are here
March 20, 2013
Panel VI: Overview and Discussion of Main Points and Closing Remarks
12:25 -- 2:50 P.M. Panel VI: Overview and Discussion of Main Points
A co-moderator from each panel will identify the main points from their respective sessions. These points will be discussed by the panel participants and the audience and will be useful for HHS, other governments and research funders to approach decisions about pursuing HPAI H5N1 gain-of-function research. These discussions will be an important contribution to the ongoing global dialog on this issue.
Robbert Dijkgraaf, Ph.D.
Co-chair, InterAcademy Council
Past President, the Royal Netherlands Academy of Arts and Sciences, the Netherlands
Director and Leon Levy Professor, Institute for Advanced Study, Princeton, USA
Harvey Fineberg, M.D., Ph.D.
President, Institute of Medicine, National Academies Professor of Health Policy
Nancy Cox, Ph.D.
Director, Influenza Division, Office of Infectious Diseases, Centers for Disease Control and Prevention, USA
Dennis Dixon, Ph.D.
Chief, Bacteriology and Mycology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
Kirsten Jacobsen, Ph.D.
Manager, Biosafety Risk Assessment, Pathogen Regulation Directorate, Public Health Agency, Canada
Amy P. Patterson, M.D.
Associate Director for Science Policy, National Institutes of Health, USA
Zarifah Reed, M.D.
Medical Director, SENTINEXT Therapeutics, Malaysia
Nariyoshi Shinomiya, M.D., Ph.D.
Professor, National Defense Medical College, Japan
Samuel Stanley, M.D.
President, Stony Brook University, Chair, National Science Advisory Board for Biosecurity, USA
Kanta Subbarao, M.D., M.P.H.
Chief, Emerging Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
Robert Webster, Ph.D.
Department of Infectious Disease, St. Jude Children's Research Hospital, USA
This page last reviewed on April 20, 2015